Sunosi® third quarter U.S. net sales of $16.8 million
Auvelity™ launched and available in U.S. pharmacies
SHARP study results announced demonstrating statistically significant improvement in cognitive function with Sunosi versus placebo
ADVANCE-2 trial of AXS-05 in Alzheimer’s disease agitation initiated
Successful Type A meeting completed for AXS-07 for the acute treatment of migraine
Company to host conference call today at 8:00 AM Eastern
Financial Guidance
- Axsome believes that its current cash, along with the remaining committed capital from the $300 million term loan facility, is sufficient to fund anticipated operations into 2025, based on the current operating plan, which includes the continued commercialization of Sunosi and Auvelity.
- Axsome expects that its operating expenses will increase year over year as the Company commercializes Sunosi and Auvelity and continues to advance its pipeline.
Conference Call Information
Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss third quarter 2022 financial results as well as to provide a corporate update. To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic). The live webcast can be accessed on the "Webcasts & Presentations" page of the "Investors" section of the Company’s website at axsome.com. A replay of the webcast will be available for approximately 30 days following the live event.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.